Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.50 |
| ▸ | BAG3 | O95817 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175992 | 1.00 | SLC2A1 (0.69) | SLC2A1ALDH1A1GAASMN1; SMN2HSD17B3 | |
| SCHEMBL12406487 | 1.00 | SLC2A1 (0.69) | SLC2A1ALDH1A1GAASMN1; SMN2HSD17B3 | |
| SCHEMBL2171533 | 0.87 | SLC2A1 (0.69) | SLC2A1ALDH1A1GAASMN1; SMN2AKR1B1 | |
| SCHEMBL12406483 | 0.87 | SLC2A1 (0.69) | SLC2A1ALDH1A1GAASMN1; SMN2AKR1B1 | |
| SCHEMBL2171529 | 0.87 | SLC2A1 (0.69) | SLC2A1ALDH1A1GAASMN1; SMN2AKR1B1 | |
| SCHEMBL2172182 | 0.86 | SLC2A1 (0.78) | SLC2A1ALDH1A1SMN1; SMN2AKR1B1S1PR1 | |
| SCHEMBL12406452 | 0.86 | SLC2A1 (0.78) | SLC2A1ALDH1A1SMN1; SMN2AKR1B1S1PR1 | |
| SCHEMBL2172187 | 0.86 | SLC2A1 (0.78) | SLC2A1ALDH1A1SMN1; SMN2AKR1B1S1PR1 | |
| SCHEMBL12406491 | 0.85 | SLC2A1 (0.77) | SLC2A1ALDH1A1SMN1; SMN2AKR1B1S1PR1 | |
| SCHEMBL1612988 | 0.85 | SLC2A1 (0.77) | SLC2A1ALDH1A1SMN1; SMN2AKR1B1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | claimed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | claimed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | claimed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | claimed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | claimed |
| EP-2254576-B1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | UNIV OHIO STATE RES FOUND (US) | 2013-08-28 | — | — | EP | disclosed |
| US-7973062-B2 | Androgen receptor-ablative agents | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2254576-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | The Ohio State University Research Foundation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009105621-A1 | ANDROGEN RECEPTOT-ABLATIVE AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291992-A1 | ANDROGEN RECEPTOR-ABLATIVE AGENTS | AR, ESRRB, KLK3 | SLC2A1 2158/4885ALDH1A1 96/4885GAA 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.